Androgen Deprivation Therapy Market Size and Growth Forecast for Businesses 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Androgen Deprivation Therapy Market Size During 2025–2029?

The androgen deprivation therapy market size has experienced significant growth in recent years. It is projected to expand from $7.81 billion in 2024 to $8.31 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.3%. The expansion observed in the historic period can be attributed to the rising incidence of prostate cancer globally, an increasing aging male population, the high recurrence rate of prostate cancer, improved survival rates encouraging long-term treatment, and growing awareness about early prostate cancer screening.

The androgen deprivation therapy market size is projected to experience robust growth in the upcoming years. Its valuation is anticipated to reach $10.49 billion by 2029, showing a compound annual growth rate (CAGR) of 6.0%. This expansion during the forecast period is driven by factors such as the increasing adoption of combination therapies in oncology, a rising prevalence of hormone-sensitive cancers, high rates of localized and advanced prostate cancer diagnosis, the expanding utilization of ADT in non-oncological hormonal conditions, and a growing patient preference for non-invasive treatment options. Significant trends expected in the forecast period include advancements in depot formulations and delivery methods, the development of oral ADT drugs, the emergence of long-acting ADT injectables, the introduction of novel androgen receptor inhibitors, and technological innovations in digital pathology and diagnostics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

What Are The Top Growth Drivers Impacting The Androgen Deprivation Therapy Market Outlook?

The anticipated rise in prostate cancer cases is projected to stimulate expansion within the androgen deprivation therapy market in the foreseeable future. This particular cancer develops in the prostate gland, an organ within the male reproductive system that produces seminal fluid. The uptick in its occurrence is primarily linked to extended life expectancies, given that advanced age substantially elevates the likelihood of contracting the illness. Androgen deprivation therapy (ADT) serves as a key therapeutic approach for prostate cancer, designed to reduce androgen concentrations which fuel tumor proliferation. This treatment is often employed in advanced or metastatic phases to impede the advancement of the condition. A notable example illustrating this trend is provided by a report from Prostate Cancer UK, a UK-based prostate cancer research, awareness, and support organization. As published in January 2025, data for England showed an increase in prostate cancer diagnoses from 50,751 cases in 2022 to 55,033 cases in 2023, underscoring a distinct year-on-year increase in prevalence. Consequently, the growing frequency of prostate cancer is indeed propelling the expansion of the androgen deprivation therapy market.

What Are The Emerging Segments Gaining Attention In The Androgen Deprivation Therapy Market?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

What Are The Latest Industry Trends Transforming The Androgen Deprivation Therapy Market?

Major companies operating in the androgen deprivation therapy market are prioritizing the development of advanced solutions, such as combination therapies, to enhance treatment effectiveness in advanced prostate cancer. This approach involves utilizing more than one type of treatment, for example, hormone therapy combined with chemotherapy, to improve therapeutic outcomes and slow the disease’s progression. As an illustration, in August 2022, Bayer AG, a Germany-based life sciences company, obtained U.S. Food and Drug Administration approval for darolutamide’s additional indication, when used in conjunction with docetaxel, for treating metastatic hormone-sensitive prostate cancer (mHSPC). The recently approved combination therapy aims to improve survival rates and defer disease advancement in individuals with metastatic hormone-sensitive prostate cancer (mHSPC), a condition where cancer has spread but continues to respond to hormone treatment. A key component of this therapy is darolutamide, an oral medication designed to target androgen receptors. Its distinctive molecular structure enables it to firmly bind to these receptors. By doing so, it efficiently inhibits their activity, thereby helping to suppress the growth and spread of prostate cancer cells.

Who Are The Prominent Global Companies Shaping The Androgen Deprivation Therapy Market?

Major companies operating in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., Lawley Pharmaceuticals Pty Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Androgen Deprivation Therapy Market?

North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Androgen Deprivation Therapy Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp

Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2025, By The Business Research Company

Hormone Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Testosterone Replacement Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report

Drugs For Hormonal Replacement Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795